The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
There is significant variation in prescriptions among countries in clinical practice for the treatment of comorbidities associated with autism spectrum disorder (ASD). It has been suggested that many people with mental health disorders in low‐/middle‐income countries do not receive adequate treatment. Hence, this study investigated psychopharmacological treatment patterns for ASD comorbidities in 30 countries and the association between country's income and prescription rates. The IMS Prescribing Insights database was used to investigate prescription patterns for ASD comorbidity treatment from 2007 to 2012. Data were obtained from 30 countries in continents of E urope, A sia, O ceania, C entral A merica, S outh A merica, and A frica. The gross domestic product (GDP) per capita was used as a proxy for each country's income. S pearman correlation was used to examine the association between prescription rate and GDP per capita. The highest prescription rates were found in W estern E urope (3.89–36.36/10,000) while the lowest prescription rates were found in A sian countries, such as T urkey, I ndonesia, S audi A rabia, and P akistan (0.04–0.82/10,000). The most commonly prescribed drug for ASD comorbidity treatment in most of the countries was risperidone, but antidepressants and antiepileptic drugs were also frequently prescribed. There was a significant positive correlation between GDP per capita and prescription rate (S pearman ρ = 0.60; P = 0.0011; 95% confidence interval 0.27–0.81), that is, the higher the GDP per capita, the higher the prescription rate. There are marked international differences in prescription rates, and this is partially accounted by economic factors. Future research should combine more data for ASD comorbidity treatment to explore the disparity of psychopharmacological treatment between countries. Autism Res 2014, 7: 543–554. © 2014 International Society for Autism Research, Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Autism and Other Pervasive Developmental Disorders
Elsabbagh, M., Divan, G., Koh, Y., Kim, Y. S., Kauchali, S., Marcín, C., Montiel‐Nava, C., Patel, V., Paula, C. S., Wang, C., et al. (2012) · Autism Research · doi:10.1002/aur.239 · Cited by 2,636
Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D., & Charman, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69041-7 · Cited by 2,104
Self-citationWang, P. S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Borges, G., Bromet, E. J., Bruffaerts, R., de Girolamo, G., de Graaf, R., Gureje, O., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61414-7 · Cited by 1,655 · cited 3×
“In addition to limited access to health services, patients who were treated for mental health disorders also received less follow-up care in low-/middle-income countries [Wang et al., 2007].”
BackgroundResultManagement of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007
Kogan, M. D., Blumberg, S. J., Schieve, L. A., Boyle, C. A., Perrin, J. M., Ghandour, R. M., Singh, G. K., Strickland, B. B., Trevathan, E., & van Dyck, P. C. (2009) · Pediatrics · doi:10.1542/peds.2009-1522 · Cited by 892
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 1×
“In the United States, only risperidone and aripiprazole are approved by the Food and Drug Administration (FDA) for the treatment of irritability in children with ASD [Marcus et al., 2009; Owen et al., 2009; Shea et al., 2004].”
BackgroundLund, C., Tomlinson, M., De Silva, M., Fekadu, A., Shidhaye, R., Jordans, M., Petersen, I., Bhana, A., Kigozi, F., Prince, M., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001359 · Cited by 584
A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356 · cited 2×
“Despite insufficient evidence on the efficacy and longterm safety of psychotropic drugs for ASD treatment, various medications have been used for ASD comorbidity treatment in clinical practice such as α-adrenergic agents, β-blockers, mood stabilizers, antiepileptic medication, and antipsychotics [Hollander, Phillips,…”
BackgroundMethodPsychotropic medication use among Medicaid-enrolled children with autism spectrum disorders
Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008) · Pediatrics · doi:10.1542/peds.2007-0984 · Cited by 295
Cadman, T., Eklund, H., Howley, D., Hayward, H., Clarke, H., Findon, J., Xenitidis, K., Murphy, D., Asherson, P., & Glaser, K. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.06.017 · Cited by 264 · cited 2×
“, 2007] by minimizing core symptoms, lowering the impact of associated mental health symptoms, and reducing maladaptive behaviors [Cadman et al., 2012].”
BackgroundSelf-citationA three-country comparison of psychotropic medication prevalence in youth
Zito, J. M., Safer, D. J., Berg, L. T. D. J.-V. D., Janhsen, K., Fegert, J. M., Gardner, J. F., Glaeske, G., & Valluri, S. C. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-26 · Cited by 201
Use of psychotropic medication in children and adolescents with autism spectrum disorders
Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., Whitaker, A., & Perrin, J. M. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0900d · Cited by 191 · cited 2×
“These include France, Germany, Italy, Spain, Mexico, Brazil, Japan, Canada, the United Kingdom and the United States.”
BackgroundRosenberg, R. E., Mandell, D. S., Farmer, J. E., Law, J. K., Marvin, A. R., & Law, P. A. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-009-0878-1 · Cited by 154
Frazier, T. W., Shattuck, P. T., Narendorf, S. C., Cooper, B. P., Wagner, M., & Spitznagel, E. L. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0057 · Cited by 113 · cited 2×
“Currently, however, there are limited practical guidelines for the pharmacological treatment of associated symptoms in children and adolescents with ASD [Frazier et al., 2011].”
Background
Cited by
Loth, E., Charman, T., Mason, L., Tillmann, J., Jones, E. J. H., Wooldridge, C., Ahmad, J., Auyeung, B., Brogna, C., Ambrosino, S., et al. (2017) · Molecular Autism · doi:10.1186/s13229-017-0146-8 · Cited by 299
“Similarly, we include participants on stable medication because 30–50% [20] children and adults with ASD in Europe and up to 70% in the USA are prescribed at least one medication for features, such as aggression, anxiety, hyperactivity, or sleep problems [21].”
Self-citationAutism spectrum disorder in adults: diagnosis, management, and health services development
Murphy, C., Wilson, C. E., Robertson, D. M., Ecker, C., Daly, E. M., Hammond, N., Galanopoulos, A., Dud, I., Murphy, D., & McAlonan, G. M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s65455 · Cited by 261
Self-citationGuastella, A. J., & Hickie, I. B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.028 · Cited by 223
Autism spectrum disorder in sub‐saharan africa: A comprehensive scoping review
Franz, L., Chambers, N., von Isenburg, M., & de Vries, P. J. (2017) · Autism Research · doi:10.1002/aur.1766 · Cited by 189
“…& Hartley, 2014; Pansegrouw & Alant, 1996; Silver, 1970], within-subjects design with repeated measures [Alant et al., 2013], nonexperimental descriptive group designs of medication use [Louw, Bentley, Sorsdahl, & Adnams, 2013; Wong et al., 2014], and one qualitative design [Geils & Knoetze, 2008].”
BackgroundCan Bayesian Theories of Autism Spectrum Disorder Help Improve Clinical Practice?
Haker, H., Schneebeli, M., & Stephan, K. E. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00107 · Cited by 130
Metadata
- Authors
- Wong, A. Y. S., Hsia, Y., Chan, E. W., Murphy, D. G. M., Simonoff, E., Buitelaar, J. K., & Wong, I. C. K.
- Venue
- Autism Research
- Publisher
- Wiley
- Published
- 2014-06-03
- Volume
- 7
- Issue
- 5
- Pages
- 543-554
- ISSN
- 1939-3792 (ISSN-L)
- 1939-3806
- OpenAlex
- W2135207343
- Cited by
- 31
- References
- 14
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.